The Quotient Therapeutics team (L-R): acting COO Scott Hayton, head of genetics and target discovery Caroline Fox, president Jacob Rubens, head of platform Simon Brunner, and CEO Geoff von Maltzahn (Credit: Quotient Therapeutics)
Flagship launches first UK-based startup to uncover genes that make cells vulnerable or resistant to disease
A new biotech startup believes that genetic diversity found among the trillions of cells that comprise an individual person could hold the keys to new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
